An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration

An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration 抗VEGF药物在多灶性脉络膜炎和湿性老年性黄斑变性中的疗效观察和比较 1 first-author 1 2 1 corresp ‡Corresponding Author ‡Corresponding Author †E-mail:xiexin163@163.com †E-mail:xiexin163@163.com xiexin163@163.com Eye Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China Eye Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China Department of Ophthalmology, the First Hospital of Jiaxing, Jiaxing 314000, China Department of Ophthalmology, the First Hospital of Jiaxing, Jiaxing 314000, China Objective: 2 To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). Methods: 2 In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization. Results: 2 Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy ( P < 0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients ( Z =−2.844, P =0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy ( P < 0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later ( P > 0.05). Conclusions: 2 IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months. 目的 2 比较抗血管内皮生长因子(VEGF)药物对多灶性脉络膜炎(MFC)和湿性老年性黄斑变性(AMD)的疗效. 创新点 2 MFC是一种特发性脉络膜视网膜病变,容易并发多灶性脉络膜新生血管,治疗棘手,易复发.目前有个别病例报道证明抗VEGF对其新生血管的治疗有效果,但是缺少更多的数据比较.本文将抗VEGF药物对MFC和AMD的疗效进行对比,以了解其在不同疾病中的疗效. 方法 2 收集MFC并发络膜新生血管和AMD并发络膜新生血管患者各10名,予以玻璃体腔注射抗VEGF药物,跟踪随访患者6个月的视力变化、新生血管大小、黄斑水肿情况.随访期间采用眼底血管造影以及光学相干断层扫描进行监测,如发现有活动性脉络膜新生血管,予以再次注射. 结论 2 抗VEGF药物对MFC并发的脉络膜新生血管有良好的治疗效果,注射次数少于湿性AMD并发的新生血管治疗,且视力恢复情况也较其明显. Wet age-related macular degeneration (AMD) Multifocal choroiditis (MFC) Juxtafoveal choroidal neovascularization (CNV) Anti-vascular endothelial growth factor (VEGF) therapy 湿性老年性黄斑变性(AMD) 多灶性脉络膜炎(MFC) 血管内皮生长因子(VEGF) Introduction 1 Multifocal choroiditis (MFC) is characterized by distinct spots of inflammation in the photoreceptor-retinal pigment epithelium complex. Choroidal neovascularization (CNV) is a well-known complication of MFC, often resulting in severe vision loss (Haen and Spaide, 2008 2008 ; Thurau and Wildner, 2010 2010 ). Many treatment options have been proposed for MFC-related CNV including steroids, immunosuppressants, photodynamic therapy, and surgical excision (Hochman et al., 1999 1999 ; Gerth et al., 2006 2006 ; Jutley et al., 2011 2011 ; D'Ambrosio et al., 2014 2014 ). However, these methods are not always sufficiently effective and some uncontrolled sub-or juxtafoveal CNVs may remain, significantly decreasing visual function, which is obviously an urgent and serious problem. Wet age-related macular degeneration (AMD)—also called neovascular AMD—is characterized by CNV which may result in blurred vision in the center of the visual field, typically occurring in older people (Lim et al., 2012 2012 ). It has been shown that anti-vascular endothelial growth factor (VEGF) therapy is successful in treating CNV for AMD (Cheung and Wong, 2011 2011 ). Recently, Julián et al. ( 2011 2011 ) and Iannetti et al. ( 2013 2013 ) studied the administration of anti-VEGF agents for CNV related to MFC, with promising results. However, MFC is rare, so comparisons of the treatment outcomes between MFC and wet AMD following anti-VEGF therapy have rarely been reported. In the present study, we aimed to examine the clinical therapeutic effect of anti-VEGF therapy on the outcomes of CNV secondary to MFC, and to compare this with its effect on wet AMD. Methods 1 Patients with juxtafoveal CNV secondary to MFC and wet AMD 2 We selected 20 consecutive patients (12 males and 8 females) with juxtafoveal CNV who had attended the Eye Center at the Second Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang Province, China, between 2013 and 2015. The patients were grouped according to etiology: 10 were affected with MFC, while 10 had wet AMD. All patients were informed of the usage of the agent (ranibizumab) and its potential benefits and side effects. The study adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board. Patients with juxtafoveal CNV secondary to MFC were recruited, and all underwent a complete ophthalmic examination. The inclusion criteria were as follows: a diagnosis of MFC, evidence of classic or occult CNV confirmed by fundus fluorescein angiography (FFA), and progressive vision loss related to the juxtafoveal neovascular manifestation after achieving strict control of intraocular inflammation with steroids and immunosuppressant treatments. The diagnosis of MFC was based on the presence of multiple chorioretinal lesions ranging in size from 50 to 350 μm, located in the posterior pole and/or the periphery zone, with the possible presence of vitreous cells and signs of anterior uveitis, as well as atrophy or peripapillary changes. The exclusion criteria were as follows: features and conditions such as AMD, pathological myopia, trauma, hereditary retinal disorders, any who previously have undergone photodynamic or anti-VEGF therapy. Wet AMD was confirmed by FFA and optical coherence tomography (OCT). FFA was used to visualize the leakage of blood behind the macula and OCT was used to observe the neovascularization lesion. Those patients who had ever previously undergone photodynamic therapy or other retinal surgeries were excluded. All cases of MFC and wet AMD had identical investigations at baseline and follow-up visits. Treatment approach 2 The decision to initiate intravitreal (IVT) injections was based on the progression of the CNV lesion and visual damage. All MFC patients had undergone strict control of intraocular inflammation—using steroids and immunosuppressant treatments—before IVT injections. However, the CNV was still present or had progressed, severely affecting visual function. Patients in both groups received IVT injections of 0.5 mg/0.05 ml ranibizumab (Novartis Pharma Schweiz AG, Switzerland). Retreatment injections were carried out during the follow-up period when the OCT showed intra-and sub-retinal fluid and the FFA revealed leakage. The data were collected at several time points: before the initial treatment and 1, 2, 3, and 6 months after the first IVT injection. Antibiotic eye drops, such as levofloxacin, were used before and after the injections. Outcome measurement 2 Slit lamp assessment, FFA, and Cirrus HD-OCT (Version 6.0; Carl Zeiss Meditec, Dublin, CA, USA) were performed for all patients before they received IVT ranibizumab and 1, 2, 3, and 6 months after the first IVT injection. Treatment success was defined as inactive CNV lesions (no leakage on FFA and shrinking on OCT). Macular edema was evaluated via OCT. Visual outcomes were evaluated using a logMAR chart, in order to determine whether visual function was decreased, maintained, or improved by treatment. Statistical methods 2 All data were collected and analyzed using Statistical Package for the Social Sciences (SPSS) software, Version 18.0 (SPSS Inc., Chicago, IL, USA). They were examined for normality using the Kolmogorov-Smirnov test, while the Mann-Whitney test was used to assess data of non-normal distribution. A paired t -test was used before and after anti-VEGF therapy, and an independent samples test was used for comparison between the two groups. Results 1 CNV lesion changes before and after anti-VEGF therapy 2 FFA detected no fluorescein leakage or macular edema at the end of the follow-up period in any patients, and no systemic or ocular side effects were registered during anti-VEGF therapy. Fig. 1 1 shows the clinical outcomes with regard to the right eye of a patient in the MFC group, before and 6 months after anti-VEGF therapy. Chorioretinal spots were visible on the color photography (Figs. 1a and 1b 1a and 1b ). Macular OCT demonstrated significant changes in the macular CNV lesion in a before-and-after comparison (Figs. 1c and 1d 1c and 1d ). FFA showed fluorescein leakage due to the CNV lesion before anti-VEGF therapy, but no leakage at the 6-month examination (Figs. 1e and 1f 1e and 1f ). (a, b) Color fundus photographs showing retinal inflammatory lesion (arrowheads) before and six months after the anti-VEGF therapy. (c, d) Spectral domain (SD)-OCT showing the CNV before anti-VEGF therapy disrupting the RPE and extending up to the level of the inner plexiform layer, and the lesion regressing six months after anti-VEGF therapy (arrowheads). (e, f) Fluorescein angiogram showing leakage from the CNV with fuzzy borders and staining of other atrophic lesions (arrowheads) Comparison of injection number between MFC and wet AMD 2 In the MFC group, five patients received only one injection, two patients received two injections at monthly intervals, and the remaining three patients received three injections at monthly intervals. The mean number of anti-VEGF injections per eye in the MFC group was 1.6. In the wet AMD group, one patient received two injections at monthly intervals, one patient received four injections at monthly intervals, and the remaining eight patients received three injections at monthly intervals. There was a mean number of three anti-VEGF injections per eye in the wet AMD group. There was a statistically significant difference of injection number between the two groups ( Z =−2.844, P =0.009). Table 1 1 summarizes the characteristics of the two groups of patients. MCF: multifocal choroiditis; AMD: macular degeneration. Mann-Whitney text (comparison between groups MCF and AMD): Z =−2.844, P =0.009 Case Disease Age (year) Sex Eye Number of injections * * 1 MCF 25 Male Left 1 2 MCF 21 Female Right 1 3 MCF 52 Male Right 1 4 MCF 29 Female Left 1 5 MCF 28 Female Right 1 6 MCF 36 Male Left 2 7 MCF 27 Female Left 2 8 MCF 50 Male Right 3 9 MCF 52 Female Right 3 10 MCF 22 Female Right 3 11 AMD 79 Male Left 4 12 AMD 62 Female Right 3 13 AMD 80 Male Right 3 14 AMD 60 Male Right 3 15 AMD 52 Male Right 2 16 AMD 72 Female Right 3 17 AMD 58 Male Right 3 18 AMD 63 Male Right 3 19 AMD 77 Male Right 3 20 AMD 57 Male Right 3 BCVA and CMT changes before and after anti-VEGF therapy 2 Best-corrected visual acuity (BCVA) and central macular thickness (CMT) showed a normal distribution before initiation of anti-VEGF therapy and 6 months after treatment ( P > 0.05), and are expressed as mean±standard deviation (Table 2 2 ). There was no statistically significant difference between the BCVA (logMAR) at baseline in the MFC group and between the wet AMD group ( P =0.376), while a significant difference was observed between the BCVA (logMAR) in the MFC group and that in the wet AMD group, 6 months after anti-VEGF therapy ( P< 0.001). There was no statistically significant difference in CMT between the two groups, either at baseline or 6 months after anti-VEGF therapy (all P > 0.05). BCVA: best-corrected visual acuity; CMT: central macular thickness; MCF: multifocal choroiditis; AMD: macular degeneration. Data are expressed as mean±standard deviation ( n =10) 2 Group 2 BCVA (logMAR) 2 CMT (μmol/L) Baseline Six months later Baseline Six months later MCF 0.58±0.39 0.13±0.19 307.90±113.42 239.10±56.13 AMD 0.73±0.32 0.68±0.25 305.10±115.80 273.90±69.66 The BCVA and CMT baseline characteristics were compared between the initial evaluation and 6 months after anti-VEGF injections. As Table 2 2 shows, there was a significant difference in BCVA (logMAR) and CMT between baseline and 6 months after anti-VEGF therapy in the MFC group ( t =5.063, P =0.001 and t =7.314, P =0.046, respectively). Moreover, a significant difference in CMT between baseline and 6 months after anti-VEGF therapy was observed in the wet AMD group ( t =4.079, P =0.003). However, no statistically significant difference in BCVA was found in the wet AMD group between baseline and 6 months after anti-VEGF therapy ( t =0.400, P =0.698). Discussion 1 MFC is a chronic disease with a high risk of CNV (Kuo and Cunningham, 2000 2000 ), a common cause of severe vision loss, and steroids and immunosuppressants are the traditional treatments for this disease. However, in all of our study patients, CNV secondary to MFC still developed and caused vision loss, even after strict control of intraocular inflammation had been achieved using steroids and immunosuppressant treatments. This phenomenon was documented by Dunlop et al. ( 1998 1998 ), who reported that the possible causes were chronic perivascular B-cell lymphocytic infiltration and breakage of Bruch’s membrane. Perentes et al. ( 2002 2002 ) reported that inflammation may cause the release of chemokines that induce angiogenesis. Further, as mentioned in Table 3 3 , photodynamic therapy could not improve visual acuity (VA) in all patients, but it remained stable. Shimada et al. ( 2008 2008 ) identified VEGF overexpression in samples of active CNV obtained after surgical excision in MFC patients. Therefore, it appears that anti-neovasculature therapy is theoretically required, as conventional therapy does not adequately prevent the development of CNV in some MFC cases. MCF: multifocal choroiditis; PIC: punctate inner choroidopathy; MIC: multifocal inner choroiditis Treatment Disease Year Country Improvement in BCVA (% of cases) Reference Anti-VEGF MCF 2017 China 7/7 Present study Systemic oral prednisolone PIC, MIC 1998 UK 7/10 Flaxel et al., 1998 1998 Surgical removal Ocular histoplasmosis syndrome 1994 USA 56/67 Thomas et al., 1994 1994 Photodynamic therapy MCF 2002 USA 4/7 Spaide et al., 2002 2002 VEGF is a type of growth factor specific for endothelial cells and a regulator of angiogenesis. High levels of VEGF expression are involved in the ocular neovascularization process; therefore, blocking these potent factors may be a new treatment for ocular neovascular diseases (Starita et al., 2007 2007 ). VEGF inhibition was initially approved by the United States Food and Drug Administration (FDA) for the treatment of CNV due to AMD. The role of VEGF inhibition in diabetic retinopathy, wet AMD, and retinal vein occlusions has since been widely studied. However, relatively few studies have examined inflammatory CNV (Gulati et al., 2011 2011 ; Rouvas et al., 2011 2011 ), and evidence-based guidelines on anti-VEGF treatment for MFC are still lacking. The results of the present study are encouraging, as the CNV lesions in all ten MFC patients developed continuously into scars and no active lesions were detected at the final examination. Furthermore, all patients showed a significant improvement in BCVA and their OCT macular thickness measurements were significantly improved compared to baseline values in the MFC group. Previous studies have also used anti-VEGF therapy for certain cases. For example, Dardabounis and Panos ( 2013 2013 ) reported the successful treatment of peripapillary CNV in a 54-year-old woman with MFC, and Fine et al. ( 2009 2009 ) reported that anti-VEGF agents were effective in improving VA over 6 months in six patients with MFC-associated CNV. Consequently, the use of anti-VEGF therapy in CNV due to MFC may prove to be a beneficial treatment. The average number of injections in MFC patients in our study was 1.6, which was fewer than that used in wet AMD, which was similar to cases reporting treatment for wet AMD (Alexandru and Alexandra, 2016 2016 ). The possible reasons for this are as follows. First, the CNV in these MFC patients was driven by two factors—previous inflammatory status and VEGF signaling. Kwak et al. ( 2000 2000 ) pointed out that VEGF signaling plays a critical role in the development of CNV. It has been shown that VEGF and extravascular inflammatory components are present in neovascular membranes (Tsutsumi-Miyahara et al., 2004 2004 ). All the patients in the present study had already achieved strict control of intraocular inflammation with steroids and immunosuppressants before the administration of ranibizumab, and none had cellular activity in the anterior chamber or in the vitreous humor, so the extravascular inflammatory components of the neovascular membrane were controlled. Ranibizumab was used to inhibit VEGF signaling. Second, the median age of our patients was 36 years, while AMD patients are usually aged over 50 years. Younger people are much more likely than older people to recover vision. As an important cause of vision loss among people younger than 50 years, untreated inflammatory CNV can cause a rapid decline, and the prognosis is poor in this population (Miller and Singerman, 2006 2006 ). Our study showed good clinical results for CNV secondary to MFC, highlighting the potential utility of anti-VEGF therapy in treating inflammatory CNV. References MR Alexandru , NM Alexandra . Wet age related macular degeneration management and follow-up . Rom J Ophthalmol , 2016 . 60 ( 1 ): 9 - 13 . 27220225 . Wet age related macular degeneration management and follow-up CM Cheung , TY Wong . Ranibizumab and bevacizumab for AMD . N Engl J Med , 2011 . 365 ( 23 ): 2237 22150050 DOI: 10.1056/NEJMc1107895 http://doi.org/10.1056/NEJMc1107895 . Ranibizumab and bevacizumab for AMD E D'Ambrosio , P Tortorella , L Iannetti . Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy . J Ophthalmol, 2014:450428 , 2014 . DOI: 10.1155/2014/450428 http://doi.org/10.1155/2014/450428 . Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy D Dardabounis , GD Panos . Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome . BMJ Case Rep, 2013: bcr2013009572 , 2013 . DOI: 10.1136/bcr-2013-009572 http://doi.org/10.1136/bcr-2013-009572 . Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome AA Dunlop , IA Cree , S Hague , 等 . Multifocal choroiditis: clinicopathologic correlation . Arch Ophthalmol , 1998 . 116 ( 6 ): 801 - 803 . 9639453 DOI: 10.1001/archopht.116.6.801 http://doi.org/10.1001/archopht.116.6.801 . Multifocal choroiditis: clinicopathologic correlation HF Fine , I Zhitomirsky , KB Freund , 等 . Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis . Retina , 2009 . 29 ( 1 ): 8 - 12 . 18784620 DOI: 10.1097/IAE.0b013e318187aff9 http://doi.org/10.1097/IAE.0b013e318187aff9 . Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis CJ Flaxel , SL Owens , B Mulholland , 等 . The use of corticosteroids for choroidal neovascularisation in young patients . Eye , 1998 . 12 266 - 272 . 9683952 . The use of corticosteroids for choroidal neovascularisation in young patients C Gerth , G Spital , A Lommatzsch , 等 . Photodynamic therapy for choroidal neovascularization in patients with multifocal choroiditis and panuveitis . Eur J Ophthalmol , 2006 . 16 ( 1 ): 111 - 118 . 16496254 DOI: 10.1177/112067210601600118 http://doi.org/10.1177/112067210601600118 . Photodynamic therapy for choroidal neovascularization in patients with multifocal choroiditis and panuveitis N Gulati , F Forooghian , R Lieberman , 等 . Vascular endothelial growth factor inhibition in uveitis: a systematic review . Br J Ophthalmol , 2011 . 95 ( 2 ): 162 - 165 . 20494915 DOI: 10.1136/bjo.2009.177279 http://doi.org/10.1136/bjo.2009.177279 . Vascular endothelial growth factor inhibition in uveitis: a systematic review SP Haen , RF Spaide . Fundus autofluorescence in multifocal choroiditis and panuveitis . Am J Ophthalmol , 2008 . 145 ( 5 ): 847 - 853 . 18329623 DOI: 10.1016/j.ajo.2008.01.008 http://doi.org/10.1016/j.ajo.2008.01.008 . Fundus autofluorescence in multifocal choroiditis and panuveitis MA Hochman , JJ Weiter , MR Fleckner , 等 . Surgical management of choroidal neovascular membranes . Int Ophthalmol Clin , 1999 . 39 303 - 315 . 10083925 . Surgical management of choroidal neovascular membranes L Iannetti , MP Paroli , C Fabiani , 等 . Effects of intravitreal bevacizumab on inflammatory choroidal neovascular membrane . Eur J Ophthalmol , 2013 . 23 ( 1 ): 114 - 118 . 22890601 DOI: 10.5301/ejo.5000192 http://doi.org/10.5301/ejo.5000192 . Effects of intravitreal bevacizumab on inflammatory choroidal neovascular membrane K Julián , C Terrada , C Fardeau , 等 . Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results . Acta Ophthalmol , 2011 . 89 ( 2 ): 179 - 184 . 21348964 DOI: 10.1111/j.1755-3768.2010.02046.x http://doi.org/10.1111/j.1755-3768.2010.02046.x . Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results G Jutley , G Jutley , V Tah , 等 . Treating peripapillary choroidal neovascular membranes: a review of the evidence . Eye , 2011 . 25 ( 6 ): 675 - 681 . 21394119 DOI: 10.1038/eye.2011.24 http://doi.org/10.1038/eye.2011.24 . Treating peripapillary choroidal neovascular membranes: a review of the evidence IC Kuo , ET Cunningham . Ocular neovascularization in patients with uveitis . Int Ophthalmol Clin , 2000 . 40 ( 2 ): 111 - 126 . 10791260 DOI: 10.1097/00004397-200004000-00009 http://doi.org/10.1097/00004397-200004000-00009 . Ocular neovascularization in patients with uveitis N Kwak , N Okamoto , JM Wood , 等 . VEGF is major stimulator in model of choroidal neovascularization . Invest Ophthalmol Vis Sci , 2000 . 41 ( 10 ): 3158 - 3164 . 10967078 . VEGF is major stimulator in model of choroidal neovascularization LS Lim , P Mitchell , JM Seddon , 等 . Age-related macular degeneration . Lancet , 2012 . 379 ( 9827 ): 1728 - 1738 . 22559899 DOI: 10.1016/S0140-6736(12)60282-7 http://doi.org/10.1016/S0140-6736(12)60282-7 . Age-related macular degeneration DG Miller , LJ Singerman . Vision loss in younger patients: a review of choroidal neovascularization . Optom Vis Sci , 2006 . 83 ( 5 ): 316 - 325 . 16699445 DOI: 10.1097/01.opx.0000216019.88256.eb http://doi.org/10.1097/01.opx.0000216019.88256.eb . Vision loss in younger patients: a review of choroidal neovascularization Y Perentes , CC Chan , E Bovey , 等 . Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease . Klin Monbl Augenheilkd , 2002 . 219 ( 4 ): 311 - 314 . 12022026 DOI: 10.1055/s-2002-30662 http://doi.org/10.1055/s-2002-30662 . Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease A Rouvas , P Petrou , M Douvali , 等 . Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization . Retina , 2011 . 31 871 - 879 . 21358461 . Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization H Shimada , M Yuzawa , T Hirose , 等 . Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy . Jpn J Ophthalmol , 2008 . 52 ( 4 ): 282 - 288 . 18773266 DOI: 10.1007/s10384-008-0566-2 http://doi.org/10.1007/s10384-008-0566-2 . Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy RF Spaide , KB Freund , J Slakter , 等 . Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy . Retina , 2002 . 22 ( 5 ): 545 - 554 . 12441718 DOI: 10.1097/00006982-200210000-00003 http://doi.org/10.1097/00006982-200210000-00003 . Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy C Starita , M Patel , B Katz , 等 . Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy . Diabetic Retinopathy , 2007 . 39 122 - 148 . DOI: 10.1159/000098504 http://doi.org/10.1159/000098504 . Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy MA Thomas , JD Dickinson , NS Melberg , 等 . Visual results after surgical removal of subfoveal choroidal neovascular membranes . Ophthalmology , 1994 . 101 1384 - 1396 . 7520148 DOI: 10.1016/S0161-6420(94)31172-9 http://doi.org/10.1016/S0161-6420(94)31172-9 . Visual results after surgical removal of subfoveal choroidal neovascular membranes S Thurau , G Wildner . Choroidtis . Ophthalmologe , 2010 . 107 79 - 91 . (in German) 20069302 DOI: 10.1007/s00347-009-2116-9 http://doi.org/10.1007/s00347-009-2116-9 . Choroidtis C Tsutsumi-Miyahara , KH Sonoda , K Egashira , 等 . The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation . Br J Ophthalmol , 2004 . 88 ( 9 ): 1217 - 1222 . 15317719 . The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation Compliance with ethics guidelines Lei FENG, Jiang-hua HU, Jie CHEN, and Xin XIE declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. 10.1631/jzus.B1700535 Project supported by the National Natural Science Foundation of China (No. 81500760) 2017-10-28 2018-02-09 2022-01-05 Copyright © Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2018 2018 Journal of Zhejiang University-SCIENCE B (Biomedicine and Biotechnology) 04 19